Results from the BSL and BIT for FavOut and AbsSDP
| BSL for FavOut | BIT for FavOut | |||||
| Variables | Univariate analysis | Multivariable analysis | Multivariable analysis | |||
| No FavOut (n=222) | FavOut (n=196) | OR for FavOut (95% CI) | P value | OR for FavOut (95% CI) | OR for FavOut (95% CI) | |
| Age (years) | 50.3 (11.2) | 46.0 (11.6) | 0.97 (0.95 to 0.98) | 0.0001 | 0.96 (0.94 to 0.98) | 0.95 (0.92 to 0.97) |
| HAQ-DI | 1.1 (0.7) | 0.9 (0.6) | 0.60 (0.45 to 0.81) | <0.0001 | 0.65 (0.42 to 1.02) | 0.67 (0.42 to 1.07) |
| DAS28-ESR | 5.3 (1.2) | 5.0 (1.4) | 0.84 (0.73 to 0.98) | 0.03 | 1.25 (0.96 to 1.59) | 1.34 (1.03 to 1.75) |
| Mean total vSHS | 3.3 (5.2) | 2.1 (4.1) | 0.94 (0.89 to 0.99) | 0.02 | 0.96 (0.90 to 1.01) | 0.97 (0.92 to 1.03) |
| Patient global assessment | 64.3 (24.0) | 55.5 (24.3) | 0.99 (0.98 to 0.99) | 0.002 | 0.99 (0.97 to 1.00) | 0.99 (0.97 to 1.00) |
| Fatigue | 54.0 (26.6) | 42.2 (26.4) | 0.99 (0.98 to 0.99) | 0.0005 | 0.98 (0.97 to 0.99) | 0.98 (0.97 to 0.99) |
| Low income | 48 (23.0) | 26 (14.4) | 0.53 (0.31 to 0.88) | 0.02 | 0.53 (0.29 to 0.97) | 0.49 (0.26 to 0.91) |
| Glucocorticoids (ever vs never exposed) | 159 (71.6) | 129 (65.8) | 0.76 (0.50 to 1.15) | 0.2 | – | 1.05 (0.62 to 1.79) |
| csDMARDs (ever vs never exposed) | 205 (92.3) | 169 (86.2) | 0.52 (0.27 to 0.98) | 0.04 | – | 0.55 (0.25 to 1.20) |
| bDMARDs (ever vs never exposed) | 93 (41.9) | 57 (29.1) | 0.57 (0.38 to 0.85) | 0.006 | – | 0.39 (0.23 to 0.67) |
| BSL for AbsSDP | BIT for AbsSDP | |||||
| Variables | Univariate analysis | Multivariable analysis | Multivariable analysis | |||
| No AbsSDP (n=252) | AbsSDP (n=91) | OR for AbsSDP (95% CI) | P value | OR for AbsSDP (95% CI) | OR for AbsSDP (95% CI) | |
| Mean total vSHS | 1.8 (2.5) | 5.9 (7.7) | 0.82 (0.76 to 0.88) | <0.0001 | 0.82 (0.76 to 0.88) | 0.82 (0.75 to 0.88) |
| CRP | 18.1 (28.3) | 25.3 (32.8) | 0.99 (0.99 to 1.00) | 0.04 | 0.99 (0.98 to 1.00) | 0.99 (0.98 to 1.00) |
| ACPA positivity | 99 (33.3) | 71 (78.0) | 0.18 (0.10 to 0.31) | <0.0001 | 0.14 (0.07 to 0.27) | 0.22 (0.10 to 0.43) |
| TJC (/28) | 10.8 (7.3) | 8.7 (6.7) | 1.05 (1.01 to 1.09) | 0.01 | 1.04 (0.99 to 1.09) | 1.04 (0.99 to 1.09) |
| Glucocorticoids (ever vs never exposed) | 161 (69.1) | 61 (73.5) | 0.73 (0.40 to 1.29) | 0.28 | – | – |
| csDMARDs (ever vs never exposed) | 196 (84.1) | 81 (97.6) | 0.14 (0.02 to 0.48) | 0.02 | – | 0.22 (0.03 to 1.05) |
| bDMARDs (ever vs never exposed) | 59 (25.3) | 51 (61.5) | 0.26 (0.15 to 0.45) | <0.0001 | – | 0.30 (0.16 to 0.56) |
Data are n (%) or mean (SD).
Low income: <610 €/month.
AbsSDP, absence of structural damage progression; ACPA, anticitrullinated peptide antibody; bDMARD, biological disease-modifying antirheumatic drug; BIT, binary treatment model; BSL, baseline model; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; FavOut, favorable outcome; HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; TJC, tender joint count; vSHS, Sharp/van der Heijde Score.